GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 3,729 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,729 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $226,611.33. Following the sale, the chief financial officer owned 39,954 shares in the company, valued at approximately $2,428,004.58. The trade was a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, June 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The shares were sold at an average price of $53.77, for a total value of $68,072.82.
• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total value of $25,554.48.

GeneDx Price Performance

Shares of GeneDx stock traded up $2.59 on Thursday, hitting $59.01. The company’s stock had a trading volume of 658,565 shares, compared to its average volume of 1,045,581. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The firm has a fifty day moving average price of $54.54 and a 200-day moving average price of $87.44. The company has a market capitalization of $1.75 billion, a P/E ratio of -22.02 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period last year, the business earned ($0.23) earnings per share. On average, equities research analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on WGS shares. Guggenheim dropped their target price on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Piper Sandler restated an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings lowered shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Finally, Craig Hallum reiterated a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in shares of GeneDx by 77.5% during the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock valued at $15,066,000 after acquiring an additional 102,456 shares during the period. California State Teachers Retirement System grew its position in shares of GeneDx by 31.2% during the first quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock worth $1,608,000 after acquiring an additional 5,951 shares during the last quarter. Ashford Capital Management Inc. increased its holdings in shares of GeneDx by 31.9% in the 1st quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock worth $11,207,000 after acquiring an additional 42,186 shares during the period. Quantinno Capital Management LP increased its holdings in shares of GeneDx by 99.2% in the 1st quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock worth $245,000 after acquiring an additional 1,897 shares during the period. Finally, First Light Asset Management LLC bought a new stake in GeneDx in the 1st quarter valued at about $15,601,000. 61.72% of the stock is currently owned by institutional investors.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Several law firms, including Rosen, Pomerantz, Bronstein Gewirtz & Grossman, Kahn Swick & Foti, Levi & Korsinsky, and Bernstein Liebhard, issued fresh reminders about the pending securities class action and the August 3 lead plaintiff deadline for GeneDx investors.
• Neutral Sentiment: The lawsuits focus on claims that investors were harmed during the April 16, 2025 to May 4, 2026 period, with allegations linked to acquisition performance and reimbursement weakness.
• Negative Sentiment: Hagens Berman highlighted that the lawsuit stems from GeneDx’s sharp post-earnings decline and a reported 94% write-off related to the Fabric Genomics acquisition, reinforcing concerns about prior results and execution. Article Title

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.